Back to search

Article

Phase II study of sodium valproate in combination with oral etoposide in platinum-resistant ovarian cancer

2022-08-02

Abstract excerpt

<title>Abstract</title> <p><bold>Background:</bold> Patients with platinum-resistant ovarian cancer (PROC) have limited therapeutic options and poor survival. There is a need for the development of newer therapies. Sodium valproic acid (VPA) is a short-chain fatty acid histone deacetylase (HDAC) inhibitor with antitumor activity in preclinical models of PROC. Synergism with conventional cytotoxic agents like etop...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
bd9fb2e4-2fb6-5936-a3b8-47a97fc06caf
DOI
10.21203/rs.3.rs-1872671/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Phase II study of sodium valproate in combination with oral etoposide in platinum-resistant ovarian cancerDOI 10.21203/rs.3.rs-1872671/v1
Sequenced Combinations of Cisplatin and Selected Phytochemicals Towards Overcoming Drug Resistance in Ovarian Tumour ModelsSemantic proximity
Could valproic acid be an effective anticancer agent? The evidence so farSemantic proximity
A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53-mutant Ovarian Cancer.Semantic proximity
Phase IIa Study of PLX2853 in Gynecologic Cancers With Known ARID1A Mutation and Phase Ib/IIa Study of PLX2853/Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer.Semantic proximity
A Phase I Dose-Escalation Study of Lobaplatin Combined with Paclitaxel in Platinum-Sensitive Recurrent Ovarian Epithelial Carcinoma: Safety, Tolerability, and Preliminary Efficacy AnalysisSemantic proximity
Exploring the anticancer potential of Vitex negundo L.: Cytotoxicity and gene regulation in PA1 ovarian cancer cellsSemantic proximity
Exploring the therapeutic use and outcome of antibody-drug conjugates in ovarian cancer treatmentSemantic proximity
A study conducted in breast cancer cells found that (valproic acid) inhibits CIP2A/C-MYC/PI3K/Akt/mTOR signaling molecules and PD-L1Semantic proximity
Dual-inhibition of NAMPT and PAK4 induces anti-tumor effects in 3D-spheroids model of platinum-resistant ovarian cancerSemantic proximity
Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients.Semantic proximity
Adverse event profile following maintenance olaparib in patients with BRCA-mutated platinum-sensitive relapsed serous ovarian cancer in the phase III SOLO2 trial.Semantic proximity
Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1I.Semantic proximity
Select a neighboring publication to make it the new centre.